Letter to Congress Regarding Legislation to Reauthorize PDUFA and MDUFA
In a letter to the U.S. Senate’s Health, Education, Labor and Pensions Committee, Public Citizen urged the Committee to consider including multiple provisions in legislation to reauthorize the Prescription Drug User Fee Act and Medical Device User Fee Amendments for fiscal years 2023 to 2027 (PDUFA VII and MDUFA V, respectively) that would strengthen the Food and Drug Administration’s independence from regulated industries and significantly enhance the agency’s regulatory oversight of prescription drugs and medical devices.
See Public Citizen’s other work regarding the drug approval process.
See Public Citizen’s other work regarding the medical device review process.